Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3062]

Interruption of endocrine therapy in young breast cancer patients does not...

Dr Ann Partridge - Dana-Farber Cancer Institute, Boston, USA

Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse ( Dr Ann Partridge - Dana-Farber Cancer Institute, Boston, USA )

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...

Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival...

Dr Monzr Al Malki - City of Hope, Duarte, USA

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or progression-free survival compared to Tac/MTX in graft-versus-host disease ( Dr Monzr Al Malki - City of Hope, Duarte, USA )

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA

Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )

Longest follow-up of patients with early breast cancer shows radiotherapy does...

Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK

Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years ( Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK )

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R...

Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma ( Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA )

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients...

Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA

Add-on parsaclisib demonstrates improvement in symptoms and SV in MV patients having a suboptimal response to ruxolitinib ( Dr Abdulraheem Yacoub - University of Kansas Cancer Center, Kansas City, USA )

A genomic assay may predict long-term prognosis in premenopausal patients with...

Dr Ruth O'Regan - University of Rochester, Rochester, USA

A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )

Breast cancer in elderly patients: a clinicopathological review of a Nigerian...

Dr Funmilola Wuraola - Obafemi Awolowo University Teaching Hospital, Ilé-Ifẹ̀...

Breast cancer in elderly patients: a clinicopathological review of a Nigerian database ( Dr Funmilola Wuraola - Obafemi Awolowo University Teaching Hospital, Ilé-Ifẹ̀, Nigeria )

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in...

Dr Sara Hurvitz - University of California, Los Angeles, USA

Trastuzumab deruxtecan shows greater OS compared to trastuzumab emtansine in patients with HER2 + mBC ( Dr Sara Hurvitz - University of California, Los Angeles, USA )

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning

Dr Shernan Holtan - University of Minnesota, Minneapolis, USA

PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )

More from ecancer